The Latest Breaking News from ADMA

3 Biotech Firms With Major Potential Catalysts in the Coming Months

The pharmaceutical industry is known for big risks and big rewards among investors; those willing to take on the risk may want to watch these firms.

MarketBeat · Jun 21

3 Mid-Cap Medical Stocks Outperforming the Market

Several mid-cap medical stocks, such as ADMA, PEN, and TMDX, are outperforming in 2025, showing resilience despite broader market weakness.

MarketBeat · May 6, 2025

There May Still Be Time to Get in on These 3 Trending Biotechs

Biotech firms as a group declined slightly in the last year amid a tough external environment, but these three companies could grow in 2025.

MarketBeat · Jan 20, 2025

ADMA Biologics's Return On Capital Employed Overview

According to data from Benzinga Pro, during Q4, ADMA Biologics's (NASDAQ:ADMA) reported sales totaled $26.38 million. Despite a 6.0% increase in earnings, the company posted a loss of $16.65 million.

Benzinga · Mar 25, 2022

ADMA Biologics' Q4 Top-Line Surpass Estimates, Concludes $175M Debt Refinancing

ADMA Biologics Inc (NASDAQ: ADMA) closed a debt refinancing with Hayfin Capital Management of $150 million, and up to an additional $25 million tied to specific revenue targets during 2022.

Benzinga · Mar 25, 2022

ADMA Biologics's Earnings Outlook

ADMA Biologics (NASDAQ:ADMA) is set to give its latest quarterly earnings report on Thursday, 2022-03-24. Here's what investors need to know before the announcement. Analysts estimate that ADMA Biologics will report an earnings per share (EPS) of $-0.09.

Benzinga · Mar 23, 2022

ADMA Biologics Shares Gain As Interim Q4 Sales Beat Expectation

ADMA Biologics Inc (NASDAQ: ADMA) expects 

Benzinga · Jan 19, 2022

The Daily Biotech Pulse: Gamida Gains On Positive Regulatory Development, Orphazyme & ADMA Preannouncements, ImmunityBio & Leap Present Positive Data

Here's a roundup of top developments in the biotech space over the last 24 hours.

Benzinga · Jan 19, 2022